Sifalimumab

Research use only, not for human use.

Sifalimumab (MEDI-545) is a monoclonal antibody that targets IFNα and suppresses abnormal immune activity by binding to interferon-alpha.Sifalimumab is used for the treatment of moderate to severe SLE.

Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research.

Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG.Cell Viability Assay Cell Line:U-87MG cells and AGS lymphocytes Concentration:3-36 μg/well Incubation Time:72 hours Result:Attenuated lymphocyte cytotoxicity triggered by IFN I (P<0.05).

Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration.Animal Model:Wild-type male BALB/c mice Dosage:30 mg/kg and 3 μg/g Administration:Subcutaneous injection; 30 mg/kg and 3 μg/g Result:Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05).Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration.

——

Chromatin/Epigenetic

COX

COX

——

——

1006877-41-3

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years